〔Abstract〕 Objective To investigate the effects of rosuvastatin enhanced lipid-lowering therapy on lipid metabolism, inflammatory factors, von Willebrand factor (vWF), thromboregulatory protein (TM) and fibrinogen to albumin ratio (FAR) of unstable angina pectoris (UAP) of coronary heart disease. Methods A total of 84 patients with UAP treated in the First Affiliated Hospital of Xinxiang Medical University from January 2021 to June 2021 were selected and divided into an observation group and a control group according to random number table method, with 42 cases in each group. The observation group was treated with rosuvastatin enhanced lipid-lowering therapy, while the control group was treated with rosuvastatin routine dose. Clinical efficacy, angina attack frequency and duration of the two groups were observed. The values of high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG), tumor necrosis factor-α (TNF-α), hypersensitive C-reactive protein (hs-CRP), interleukin-8 (IL-8), vWF, TM, FAR and medication were compared between the two groups before and after treatment security. Results After treatment the frequency and duration of angina pectoris attack in the observation group were less than those in the control group, and the differences were statistically significant (P < 0.05). After treatment, the levels of LDL-C, TC, TG, TNF-α, hs-CRP, IL-8, vWF, TM, fibrinogen (FIB) and FAR in the observation group were lower than those in the control group, while the levels of HDL-C and albumin (ALB) were higher than those in the control group, the differences were statistically significant (P < 0.05). There was no significant difference in the incidence of adverse reactions and adverse cardiac events between the two groups (P > 0.05). Conclusion Rosuvastatin enhanced lipid-lowering therapy can effectively improve angina symptoms in patients with UAP of coronary heart disease, promote lipid metabolism, and inhibit inflammatory response.